Chimeric antigen receptor (CAR) t-cell therapy - The Bloodline with Blood Cancer United Podcast

With so many new advances in acute lymphoblastic leukemia (ALL), understanding today’s treatment landscape can give patients a clearer, more hopeful outlook.

In this episode, we speak with Marlise Luskin, MD of the Dana-Farber Cancer Institute, about what adults should know when facing a diagnosis of acute lymphoblastic leukemia. Dr. Luskin helps listeners understand how ALL develops, how subtypes are identified, and why genetics play an important role in guiding treatment. She discusses current therapies including chemotherapy, targeted agents and immunotherapies including CAR T-cell therapy, as well as how care teams monitor progress and manage side effects. While ALL is a complex disease, patients and caregivers will hear clear explanations, practical information, and meaningful reasons to feel hopeful about the advances shaping ALL care today.

Mentioned on this episode: 

Additional Blood Cancer United Support Resources: 

Episode supported by Syndax Pharmaceuticals Inc.

The post Acute Lymphoblastic Leukemia (ALL): The New Tools Shaping Tomorrow first appeared on The Bloodline with Blood Cancer United Podcast.

Multiple myeloma can feel unfamiliar and overwhelming at first, but today’s advances tell a much brighter story.

In this episode, Dr. Andrew Yee of Massachusetts General Hospital explains what myeloma is, how it’s diagnosed, and why new treatment options, from four-drug regimens to CAR T-cell therapy and bispecific antibodies, are transforming patient outcomes. With enthusiasm and relatable analogies, he highlights how patients may progress from periods of significant challenges to reaching a level of stability and well‑being that allows them to live fully. This conversation offers clarity, confidence, and real optimism for anyone navigating myeloma.

Mentioned on this episode: 

Additional Blood Cancer United Support Resources: 

Episode supported by AbbVie Inc.; Bristol Myers Squibb; Genentech, A Member of the Roche Group; GSK plc.; Johnson & Johnson.

The post Facing Multiple Myeloma: A Guide to Choices, Care, and Confidence first appeared on The Bloodline with Blood Cancer United Podcast.

CAR T‑cell therapy is redefining what personalized cancer treatment can look like, offering real promise for patients and families.

In this episode, we speak with Dr. Richard Maziarz and CAR T Nurse Coordinator Bashi Ratterree of Oregon Health & Science University (OHSU). Together, they explain how CAR T‑cell therapy works, who may be eligible, what patients can expect during treatment and recovery, and the promising advancements shaping the future of this innovative therapy.

Mentioned on this episode: 

Additional Blood Cancer United Support Resources: 

Episode supported by Bristol Myers Squibb; Johnson & Johnson & Legend Biotech;  Kite, a Gilead Company; Novartis Pharmaceuticals Corporation.

The post Inside CAR T‑Cell Therapy: How Innovation Is Changing Lives first appeared on The Bloodline with Blood Cancer United Podcast.

Non-Hodgkin lymphoma (NHL) can sound overwhelming, but what does it really mean for patients and families? In this episode, we speak to Dr. Jean Koff of Winship Cancer Institute of Emory University, who breaks down the big picture of NHL: what it is, how it’s an umbrella term for multiple subtypes, and what today’s treatments and tomorrow’s innovations could mean for you. From understanding subtypes and staging to exploring options like watchful waiting, chemotherapy, and cutting-edge immunotherapies, we cover what matters most: knowledge, clarity, and hope.

Mentioned on this episode: 

Additional Blood Cancer United Support Resources: 

Supported by AbbVie Inc. and Genentech, A Member of the Roche Group.

The post The Big Picture on Non-Hodgkin Lymphoma: Treatments, Trends, and Tomorrow first appeared on The Bloodline with Blood Cancer United Podcast.

In this episode, we’re joined by Dr. Marc Hoffmann from The University of Kansas Cancer Center, to explore chronic lymphocytic leukemia (CLL)—what it is, how it’s treated today, and where research is headed. Dr. Hoffmann shares insights on treatment goals, side effect management, and the importance of shared decision making. We also touch on emerging therapies—including CAR T-cell therapy and bispecifics—and end with a message of hope for those navigating life after a CLL diagnosis.

Mentioned on this episode: 

Additional LLS Support Resources: 

Supported by AbbVie Inc., BeOne Medicines and Genentech, A Member of the Roche Group.

The post Partnering in Care: Chronic Lymphocytic Leukemia (CLL) first appeared on The Bloodline with Blood Cancer United Podcast.

Primary Central Nervous System Lymphoma (PCNSL) is a rare form of non-Hodgkin lymphoma that affects the brain, spinal cord, or eyes. In this episode, Dr. Lakshmi Nayak of Dana-Farber Cancer Institute, helps us better understand this uncommon type of lymphoma.  From early signs and symptoms to diagnosis, treatment options, and the latest clinical trials, Dr. Nayak breaks it all down in a clear and compassionate way.

Mentioned on this episode: 

Additional LLS Support Resources: 

Supported by ONO Pharmaceutical

The post Breaking Down Primary CNS Lymphoma: From Rare Diagnosis to Growing Progress first appeared on The Bloodline with Blood Cancer United Podcast.

Curious about CAR T-cell therapy? We went straight to the source for answers.

In this episode, the LLS Patient Education team visited The University of Miami Sylvester Cancer Center to meet with Dr. Trent Wang. He answered some of the most frequently asked questions from our patients and caregivers about this innovative cancer treatment – from who’s eligible and what to expect, to side effects, caregiver roles, and exciting future developments.

Mentioned on this episode: 

Additional LLS Support Resources: 

Supported by Bristol Myers Squibb; Johnson & Johnson & Legend Biotech; and Kite, a Gilead Company.

The post CAR T-cell Therapy: Your Questions Answered first appeared on The Bloodline with Blood Cancer United Podcast.

In this episode, we sit down with Dr. Bilal Abid from University of Texas Health Science Center in Houston to discuss how healthcare disparities have an effect on cancer care — especially when it comes to cutting-edge treatments such as stem cell transplantations and CAR T-cell therapy. We discuss how race, socioeconomic status, education, and geographic location can determine a patient’s access to cancer care. With travel, insurance, and systemic barriers in the mix, we explore what patients can do to navigate these challenges, and how treatment centers and policymakers are contributing to ensure equitable access to care for all patients.

Mentioned on this episode: 

Additional LLS Support Resources: 

Supported by Genentech, A Member of the Roche Group.

The post Impact of Disparity: Navigating Treatment Equality in Cancer Care first appeared on The Bloodline with Blood Cancer United Podcast.

Living with chronic lymphocytic leukemia (CLL) can be a challenging journey for both patients and caregivers.  

However, there is a beacon of hope. Tune in to our latest episode, where we speak to Dr. Mayur Narkhede of the University of Alabama about groundbreaking research and innovative treatments for CLL. Discover the potential of CAR T-cell therapy, bispecific antibodies and other cutting-edge options that bring the promise of new hope and possibilities for those affected by CLL. Don’t miss this inspiring and informative discussion! 

Mentioned on this episode: 

Additional LLS Support Resources: 

Support for this episode is provided by Genentech, Inc.

The post Hope on the Horizon: Chronic Lymphocytic Leukemia first appeared on The Bloodline with Blood Cancer United Podcast.

The treatment landscape for non-Hodgkin lymphoma has significantly evolved over the past few decades. With groundbreaking advancements in CAR T-cell therapy and bispecific antibodies, researchers are making strides toward curative treatments and enhancing patients’ quality of life.

In this episode, we speak with Dr. David Bond from The Ohio State University about the latest developments in treating both aggressive and slow-growing non-Hodgkin lymphomas. He discusses innovative, newly approved therapies for patients, as well as how improvements in supportive care better manage the physical and emotional side effects of treatment.

Mentioned on this episode: 

Additional LLS Support Resources: 

Support for this episode is provided by Genentech, Inc.

The post Innovative Therapies: Transforming Non-Hodgkin Lymphoma Care first appeared on The Bloodline with Blood Cancer United Podcast.